Filters
Term Search
You can select from the dropdown list OR enter your own terms to refine the search.
Last Updated: 10/31/2025
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 624 publications
Healthcare cost comparison between first-line ibrutinib and acalabrutinib in chronic lymphocytic leukemia patients in the Veterans Affairs.
Journal: Journal of comparative effectiveness research
Published: October 14, 2025
Correction to: Real-world efficacy and safety outcomes of acalabrutinib in chronic lymphocytic leukemia: primary results of a French multicentre observational study (NAOS).
Journal: Annals of hematology
Published: October 13, 2025
Pirtobrutinib in the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma.
Journal: Future oncology (London, England)
Published: October 03, 2025
PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; nivolumab plus ipilimumab for colorectal cancer, trastuzumab deruxtecan for breast cancer, and acalabrutinib for mantle cell lymphoma.
Journal: International journal of clinical oncology
Published: September 15, 2025
Selected drugs, therapeutic alternatives, and price benchmarks for IPAY 2027 Medicare drug price negotiation.
Journal: Journal of managed care & specialty pharmacy
Published: September 12, 2025
Zanubrutinib in the treatment of Waldenström Macroglobulinemia.
Journal: Future oncology (London, England)
Published: September 11, 2025
Real-world treatment patterns of Bruton tyrosine kinase inhibitors in mantle cell lymphoma in a community oncology setting.
Journal: Future oncology (London, England)
Published: September 08, 2025
Zanubrutinib versus acalabrutinib indirect treatment comparison in relapsed or refractory mantle cell lymphoma.
Journal: Leukemia & lymphoma
Published: September 01, 2025
Multidisciplinary approach to diagnosis and management of lymphadenopathy in a patient with mucous membrane pemphigoid: a case report.
Journal: General dentistry
Published: August 19, 2025
BTK inhibitors potently impair platelet aggregation as a class effect independent of BTK specificity or dose in CLL and MCL.
Journal: Journal of clinical and experimental hematopathology : JCEH
Published: July 30, 2025
Real-world utilization of Bruton tyrosine kinase inhibitors in relapsed/refractory chronic lymphocytic leukemia in Australia.
Journal: Leukemia & lymphoma
Published: July 27, 2025
Last Updated: 10/31/2025